Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
$5.02
-$0.19(-5.85%)
At close: 4:00 PM EST
$5.02
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.54 - $5.55
Previous CloseN/A
Volume977.37K
Average Volume (3M)8.71M
Market Cap
$1.66B
Enterprise Value$925.96M
Total Cash (Recent Filing)$549.04M
Total Debt (Recent Filing)$10.46M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Mar 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding342,833,440
10 Day Avg. Volume11,315,175
30 Day Avg. Volume8,705,940
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.54
Price to Sales (P/S)90.81
P/FCF Ratio-5.48
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue34.62
Enterprise Value/Gross Profit63.80
Enterprise Value/Ebitda-4.30
Forecast
1Y Price Target
$9.14Price Target Upside82.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial And Financial PositionNuvation ended the quarter with significant cash reserves, providing an operational runway through profitability and enabling pipeline expansion.
Efficacy And Market PenetrationThe swift uptake of IBTROZI by physicians is due to its compelling efficacy profile, positioning it as a preferred treatment option.
Regulatory Approval And GuidelinesIBTROZI has been added to the National Comprehensive Cancer Networks guidelines as a Preferred Agent for ROS1+ non-small cell lung cancer, reinforcing its potential for success.
Bears Say
Bearish Market SentimentShort interest stands at 15.5% of the float, indicating a significant level of bearish sentiment in the market.
Discontinuation And Toxicity ConcernsManagement noted that most patients discontinue therapy within two years, with about 10% of scripts being discontinued every month due to CNS toxicity.
Market CompetitionPoorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.54 and its highest was $5.55 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $1.66B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Mar 05, 2026 which is in 117 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Nov 03, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.169 by $0.009.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.1.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 342,833,440 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.169. Following the earnings report the stock price went down -6.576%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.14 (82.07% Upside)
$9.14 (82.07% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
112.06%
12-Months-Change
Fundamentals
Return on Equity
-52.49%
Trailing 12-Months
Asset Growth
5.25%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio (NUVB) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company operates within the pharmaceutical and biotechnology sectors and is dedicated to advancing a proprietary pipeline of novel oncology drug candidates. Nuvation Bio aims to address unmet medical needs by targeting multiple tumor types with its differentiated therapeutic approaches.
NUVB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a successful launch of IBTROZI with strong adoption and expansion in markets outside the U.S., alongside robust financial performance. However, challenges related to high costs and strategic decisions in the IDH1 program were noted. The positive growth and approval metrics for IBTROZI outweigh these challenges.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$9.14
▲(82.07% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
19.41% Insiders
15.99% Mutual Funds
0.03% Other Institutional Investors
55.49% Public Companies and Individual Investors